Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy

Federico  Pirro; Giacomo Caldarola; Nicoletta Bernardini; Maria Grazia  Celeste; Annunziata Dattola; Eleonora De Luca; Marco Galluzzo; Domenico Giordano; Chiara Izzi; Giulia Maretti; Lorenzo Marcelli; Roberto  Ravasio; Antonio Giovanni  Richetta; Nevena  Skroza; Marina Talamonti; Arianna Zangrilli; Luca Bianchi; Giovanni Pellacani; Severino  Persechino; Concetta Potenza; Ketty  Peris; Clara De Simone

doi:10.5826/dpc.1501a4838

Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy

Authors

Federico Pirro UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy
Giacomo Caldarola UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy
Nicoletta Bernardini Dermatology Unit “D. Innocenzi”, Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome-Polo Pontino, Latina, Italy
Maria Grazia Celeste Hospital Pharmacy, Policlinico Tor Vergata, Rome, Italy
Annunziata Dattola Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy
Eleonora De Luca UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy
Marco Galluzzo Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
Domenico Giordano Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Roma, Rome, Italy
Chiara Izzi Hospital Pharmacy, Policlinico Tor Vergata, Rome, Italy
Giulia Maretti Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy
Lorenzo Marcelli Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
Roberto Ravasio HEOR &RWE Lead, Market Access Provider, Milano, Italy
Antonio Giovanni Richetta Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy
Nevena Skroza Dermatology Unit “D. Innocenzi”, Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome-Polo Pontino, Latina, Italy
Marina Talamonti Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
Arianna Zangrilli Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
Luca Bianchi Dermatology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
Giovanni Pellacani Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy
Severino Persechino Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University of Roma, Rome, Italy
Concetta Potenza Dermatology Unit “D. Innocenzi”, Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome-Polo Pontino, Latina, Italy
Ketty Peris UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy
Clara De Simone UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy

Keywords:

efficacy, cost per responder, risankizumab, secukinumab, psoriasis

Abstract

Introduction: Risankizumab and secukinumab are effective treatment options for patients with moderate to severe psoriasis.

Objective: We sought to estimate the efficacy and the cost per responder of risankizumab and secukinumab by comparing these two drugs in a real-life setting.

Methods:.A multicentric retrospective study was conducted in patients from the Lazio region of Italy affected by moderate-to-severe psoriasis who initiated risankizumab or secukinumab between September 2020 to September 2022. Psoriasis Area and Severity Index (PASI) was measured at baseline and after 16, 52, and 78 weeks. Clinical responses were evaluated by PASI90 and PASI100 responses at the same timepoints. The cost per responder at week 16 and 52 was adopted as a cost-effectiveness indicator.

Results: Included were 141 patients, 74 (52.5%) treated with risankizumab and 67 (47.5%) treated with secukinumab. PASI90 responses in risankizumab-treated patients were higher than those observed in patients treated with secukinumab at both weeks 16 and 52 [79.7% vs 64.2% (p=0.041) and 98.6% vs 83.6% (p=0.003), respectively]. Risankizumab also showed superior PASI100 rates at week 52 (85.5% vs 65.6%, p=0.009). No statistically significant differences were observed in PASI90 and PASI100 rates between the 2 groups at week 78. The cost per PASI90 and PASI100 responder for risankizumab was lower at both weeks 16 (€5833.66 and €8394.78, compared to €8747.18 and €10746.53 for secukinumab) and 52 (€11798.90 and €13598.73 vs €15347.70 and €19568.31, respectively).

Conclusions: Risankizumab showed superior efficacy than secukinumab and a lower cost per responder.

References

Prignano F, Rogai V, Cavallucci E, et al. Epidemiology of psoriasis and psoriatic arthritis in Italy-a systematic review. Curr Rheumatol Rep. 2018;20(7):43

Gianfredi V, Casu G, Bricchi L, Kacerik E, Rongioletti F, Signorelli C. Epidemiology of psoriasis in Italy: burden, cost, comorbidities and patients' satisfaction. A systematic review. Acta Biomed. 2022;93(6):e2022332

Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM; Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020 May 28;369:m1590

Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945-1960

Alwan W, Nestle FO. Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S2-S6

Kim J, Krueger JG. Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. Annu Rev Med. 2017 Jan 14;68:255-269

Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009 Jun;129(6):1339-50

Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019 Mar 23;20(6):1475

Tokuyama M, Mabuchi T. New Treatment Addressing the Pathogenesis of Psoriasis. Int J Mol Sci. 2020 Oct 11;21(20):7488

Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015;75(3):329-338

Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338

Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017 Jan;76((1)):60–69.e9

Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 Aug 25;392(10148):650-661

McKeage K, Duggan S. Risankizumab: First Global Approval. Drugs. 2019;79(8):893-900

Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, Geng Z, Paul C. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021 Jan;184(1):50-59

Mastorino L, Dapavo P, Susca S, et al. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. J Dtsch Dermatol Ges. Published online November 5, 2023

Torres T, Puig L, Vender R, et al. Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study. Am J Clin Dermatol. 2022;23(6):891-904

Gisondi P, Loconsole F, Raimondo P, Ravasio R. Costo per responder di risankizumab e secukinumab nel trattamento della psoriasi a placche da moderata a grave in Italia. Glob Reg Health Technol Assess. 2021;8:120-130

Wu JJ, Jia X, Zhao Y, et al. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. J Dermatolog Treat. 2021;32(7):693-700

Nyholm N, Schnack H, Danø A, Skowron F. Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany. Curr Med Res Opin. 2023;39(6):833-842

Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-44

Caldarola G, Zangrilli A, Bernardini N, et al. Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study. Dermatol Ther. 2022;35(6):e15489

Brunasso AMG, Burlando M, Amoruso F, et al. Risankizumab: Daily Practice Experience of High Need Patients. Biomedicines. 2023;11(6):1769

Dastoli S, Passante M, Loconsole F, et al. Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy. J Dermatolog Treat. 2023;34(1):2200868

Thaçi D, Körber A, von Kiedrowski R, et al. Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. J Eur Acad Dermatol Venereol. 2020;34(2):310-318

Narcisi A, Valenti M, Cortese A, et al. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study. Dermatol Ther. 2022;35(2):e15228

Cortese A, Gargiulo L, Ibba L, et al. Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study. Dermatol Reports. 2023;15(3):9692

Crowley JJ, Langley RG, Gordon KB, et al. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. Dermatol Ther (Heidelb). 2022;12(2):561-575

Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018;179(2):320-328

García-Doval I, Pérez-Zafrilla B, Ferrandiz C, et al. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. J Dermatolog Treat. 2016;27(3):203-209

Gkalpakiotis S, Cetkovska P, Arenberger P, Dolezal T, Arenbergerova M, Velackova B, Fialova J, Kojanova M; BIOREP study group. Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic. Dermatol Ther (Heidelb). 2021 Jun 5:1–11

Saeki H, Ishii K, Joshi A, Bensimon AG, Yang H, Kawaguchi I. An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan. J Dermatolog Treat. 2022;33(1):229-239

Norden A, Moon JY, Javadi SS, Munawar L, Maul JT, Wu JJ. Anti-drug antibodies of IL-23 inhibitors for psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2022;36(8):1171-1177

De Simone C, Caldarola G, Maiorino A, et al. Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study. Dermatol Ther. 2016;29(5):372-376

Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181(3):450-458